457948-95-7Relevant academic research and scientific papers
Iron-Catalyzed Enantioselective Radical Carboazidation and Diazidation of α,β-Unsaturated Carbonyl Compounds
Dong, Shunxi,Feng, Xiaoming,He, Jun,Liu, Wen,Liu, Xiaohua,Pu, Maoping,Wu, Yun-Dong,Zhang, Tinghui
supporting information, p. 11856 - 11863 (2021/08/16)
Azidation of alkenes is an efficient protocol to synthesize organic azides which are important structural motifs in organic synthesis. Enantioselective radical azidation, as a useful strategy to install a C-N3 bond, remains challenging due to the inherently instability and unique structure of radicals. Here, we disclose an efficient enantioselective radical carboazidation and diazidation of α,β-unsaturated ketones and amides catalyzed by chiral N,N′-dioxide/Fe(OTf)2 complexes. An array of substituted alkenes was transformed to the corresponding α-azido carbonyl derivatives in good to excellent enantioselectivities, benefiting the preparation of chiral α-amino ketones, vicinal amino alcohols, and vicinal diamines. Control experiments and mechanistic studies proved the radical pathway in the reaction process. The DFT calculations showed that the azido transferred to the radical intermediate via an intramolecular five-membered transition state with the internal nitrogen of the Fe-N3 species.
Organocatalytic Stereoconvergent Synthesis of α-CF3 Amides: Triketopiperazines and Their Heterocyclic Metamorphosis
Foster, Robert W.,Lenz, Eva N.,Simpkins, Nigel S.,Stead, Darren
supporting information, p. 8810 - 8813 (2017/07/11)
The highly enantioselective alkylation of α-CF3 enolates, generated from triketopiperazines, has been accomplished through use of a bifunctional thiourea organocatalyst to facilitate 1,4-addition to varied enone acceptors. On treatment with appropriate nitrogen nucleophiles, the chiral triketopiperazine products undergo a metamorphosis, to provide novel fused heterocyclic lactams such as extended pyrazolopyrimidines.
Enantioselective Mannich Reaction Employing 1,3,5-Triaryl-1,3,5-triazinanes Catalyzed by Chiral-at-Metal Rhodium Complexes
Gong, Jun,Li, Shi-Wu,Qurban, Saira,Kang, Qiang
supporting information, p. 3584 - 3593 (2017/07/22)
Chiral-at-metal RhIII complexes catalyze the efficient enantioselective Mannich reaction of 2-acyl imidazoles with 1,3,5-triazinanes, affording the corresponding adducts in 81–99 % yield with up to >99 % enantioselectivity. This protocol performs with 0.1 mol-% of RhIII complex on gram scale without any loss in enantioselectivity.
4,5- DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY
-
Paragraph 0286; 0287; 0288; 0289, (2016/04/09)
The present invention relates to 4,5-dihydropyrazole derivatives of the formula (I) and physiologically tolerated salts thereof which are GlyT1 inhibitors. The invention further relates to pharmaceutical compositions comprising such 4,5-dihydropyrazole de
Iron-Catalyzed Michael Addition of Ketones to Polar Olefins
Zhang, Di-Han,Knelles, Jakob,Plietker, Bernd
supporting information, p. 2469 - 2479 (2016/08/16)
The base metal complex tetrabutylammonium nitrosyltricarbonylferrate {Bu4N[Fe(CO)3(NO)] (TBA[Fe])} – catalyzes the conjugate addition of ketones to polar olefins. The reaction is applicable to a wide range of substrates leading to interesting building blocks for organic synthesis. Clear indications for an acid-base type rather than a C?H activation pathway exist. (Figure presented.).
Use of NK-1 receptor antagonists in pruritus
-
Page/Page column 6; 7, (2014/12/12)
The invention relates to methods for treating pruritus with an NK-1 receptor antagonist. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonist.
PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
-
Paragraph 0134-0135, (2015/01/07)
Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors
Basu, Sujay,Prasad, Uppuleti Viplava,Barawkar, Dinesh A.,De, Siddhartha,Palle, Venkata P.,Menon, Suraj,Patel, Meena,Thorat, Sachin,Singh, Umesh P.,Sarma, Koushik Das,Waman, Yogesh,Niranjan, Sanjay,Pathade, Vishal,Gaur, Ashwani,Reddy, Satyanarayana,Ansari, Shariq
scheme or table, p. 2843 - 2849 (2012/05/20)
A series of novel heterocyclic carboxylic acid based protein tyrosine phosphatase 1B (PTP1B) inhibitors with hydrophobic tail have been synthesized and characterized. Structure-activity relationship (SAR) optimization resulted in identification of several
Fe(II)-catalyzed amination of aromatic C-H bonds via ring opening of 2 H-azirines: Synthesis of 2,3-disubstituted indoles
Jana, Samaresh,Clements, MacK D.,Sharp, Barry K.,Zheng, Nan
supporting information; scheme or table, p. 3736 - 3739 (2010/11/03)
A general method for the synthesis of 2,3-disubstituted indoles is described. The key feature of this method is the amination of aromatic C-H bonds via FeCl2-catalyzed ring opening of 2H-azirines. The method tolerates a variety of functional groups such as Br, F, NO2, OMe, CF3, OTBS, alkenes, and OPiv. The method can also be extended to synthesize azaindoles.
Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists
Jiang, Jinlong,Bunda, Jaime L.,Doss, Geoge A.,Chicchi, Gary G.,Kurtz, Marc M.,Tsao, Kwei-Lan C.,Tong, Xinchun,Zheng, Song,Upthagrove, Alana,Samuel, Koppara,Tschirret-Guth, Richard,Kumar, Sanjeev,Wheeldon, Alan,Carlson, Emma J.,Hargreaves, Richard,Burns, Donald,Hamill, Terence,Ryan, Christine,Krause, Stephen M.,Eng, WaiSi,DeVita, Robert J.,Mills, Sander G.
experimental part, p. 3039 - 3046 (2010/03/03)
3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy} -4-(4-fluorophenyl)octahydro-2H-isoindol-2-yl]-cyclopent-2-en-1-one (17) is a high affinity, brain-penetrant, hydroisoindoline-based neurokinin-1 (NK1) receptor antagonist with a long ce
